Buy Drugs Online:
Drugs Information:
Drugs List

1. Name Of The Medicinal Product

Ultiva (remifentanil hydrochloride) for Injection 1 mg

Ultiva (remifentanil hydrochloride) for Injection 2 mg

Ultiva (remifentanil hydrochloride) for Injection 5 mg

2. Qualitative And Quantitative Composition

Ultiva is a sterile, endotoxin-free, preservative-free, white to off white, lyophilized powder, to be reconstituted before use.

When reconstituted as directed, solutions of Ultiva are clear and colourless and contain 1mg/ml of remifentanil base as remifentanil hydrochloride.

Ultiva for injection is available in glass vials containing 1 mg, 2 mg or 5 mg of remifentanil base.

3. Pharmaceutical Form

Lyophilized powder for reconstitution for intravenous administration.

4. Clinical Particulars

4.1 Therapeutic Indications

Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision.

Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

4.2 Posology And Method Of Administration

Ultiva should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.

Continuous infusions of Ultiva must be administered by a calibrated infusion device into a fast flowing IV line or via a dedic

1. Name Of The Medicinal Product

Utovlan.

2. Qualitative And Quantitative Composition

Each tablet contains 5mg norethisterone Ph Eur.

For excipients see Section 6.1.

3. Pharmaceutical Form

White, flat, circular, bevel-edged tablet inscribed 'SEARLE' on one side and 'U' on the other.

4. Clinical Particulars

4.1 Therapeutic Indications

At low dose: Dysfunctional uterine bleeding, endometriosis, polymenorrhoea, menorrhagia, metropathia, haemorrhagia, postponement of menstruation and premenstrual syndrome.

At high dose: Disseminated carcinoma of the breast.

4.2 Posology And Method Of Administration

Oral Administration

Low dose

Dysfunctional uterine bleeding, polymenorrhoea, menorrhagia, dysmenorrhoea and metropathia haemorrhagia: 1 tablet three times daily for 10 days; bleeding usually stops within 48 hours. Withdrawal bleeding resembling true menstruation occurs a few days after the end of treatment. One tablet twice daily, from days 19 to 26 of the two subsequent cycles, should be given to prevent recurrence of the condition.

Endometriosis: 1 tablet three times daily for a minimum treatment period of six months. The dosage should be increased to 4 or 5 tablets a day if spotting occurs. The initial dosage should be resumed when bleeding or spotting stops.

Postponement of menstruation: 1 tablet three times daily, starting three days before the expected onset of menstruation. Menstruation usually follows

1. Name Of The Medicinal Product

UTROGESTAN 100MG CAPSULES

2. Qualitative And Quantitative Composition

Each capsule contains 100 mg micronised progesterone (INN). For excipients, see 6.1.

3. Pharmaceutical Form

Capsules, soft

White

4. Clinical Particulars

4.1 Therapeutic Indications

Adjunctive use with estrogen in post-menopausal women with an intact uterus. (HRT)

4.2 Posology And Method Of Administration

Posology

In women receiving estrogen replacement therapy there is an increased risk of endometrial cancer which can be countered by progesterone administration. The recommended dose is 200 mg daily at bedtime, for twelve days in the last half of each therapeutic cycle (beginning on day 15 of the cycle and ending on day 26). Withdrawal bleeding may occur in the following week. Alternatively 100 mg can be given at bedtime from day 1 to day 25 of each therapeutic cycle, withdrawal bleeding being less with this treatment schedule.

Children: Not applicable.

Elderly: As for adults

Method of Administration: Oral. Utrogestan 100mg Capsules should not be taken with food

4.3 Contraindications

Known allergy or hypersensitivity to progesterone or to any of the excipients. The capsules contain arachis oil (peanut oil) and should never be used by patients allergic to peanuts. Severe hepatic dysfunction. Undiagnosed vaginal bleeding. Mammary or genital tract carcinoma. Thrombophlebitis. Thromboembolic disorders. Cerebral haemorrhage. Porphyria.

4.4 Special Warnings And Precautions For Use

Warnings:

Utrogestan 100mg C

ULTRAMOL SOLUBLE

Paracetamol, Codeine phosphate and Caffeine

Read all of this leaflet carefully before you start taking this medicine.

Keep this leaflet. You may need to read it again

If you have further questions, please ask your doctor or pharmacist

Do not pass this medicine on to others. It may harm them, even if their symptoms are the same as yours

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What Ultramol Soluble is and what it is used for
  • 2. Before you take Ultramol Soluble
  • 3. How to take Ultramol Soluble
  • 4. Possible side effects
  • 5. How to store Ultramol Soluble
  • 6. Further information

What Ultramol Soluble Is And What It Is Used For

The name of your medicine is Ultramol Soluble. Ultramol Soluble contains three different medicines called paracetamol, codeine phosphate and caffeine. It belongs to a group of medicines called analgesics (painkillers) and is used to relieve migraines, headaches, rheumatic pain, period pains, toothache, neuralgia (nerve pain), sore throats and the symptoms of cold and flu.

Before You Take Ultramol Soluble

Important things you should know about Ultramol Soluble

  • If you need to use this medicine for more than three days at a time, see your doctor
  • Taki

1. Name Of The Medicinal Product

Ucerax Syrup 10 mg/5ml.

2. Qualitative And Quantitative Composition

Each ml contains hydroxyzine hydrochloride 2 mg/ml.

For excipients, see 6.1.

3. Pharmaceutical Form

Syrup.

Clear colourless solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Ucerax is indicated to assist in the management of anxiety.

Ucerax is indicated to assist in the management of pruritus associated with acute and chronic urticaria, including cholinergic and physical types, and in atopic and contact dermatosis in adults and children.

4.2 Posology And Method Of Administration

Adults:

Anxiety.

50 mg/day in 3 separate administrations of 12.5-12.5-25mg. In more severe cases, doses up to 300mg/day can be used.

Pruritus.

Starting dose of 25 mg at night, increasing as necessary to 25 mg three or four times daily.

The maximum single dose in adults should not exceed 200mg whereas the maximum daily doses should not exceed 300mg.

Children:

Children aged from 12 months to 6 years: 1mg/kg/day up to 2.5mg/kg/day in divided doses.

Children aged over 6 years: 1mg/kg/day up to 2mg/kg/day in divided doses.

The dosage should be adjusted according to the patient's response to therapy.

In the elderly, it is advised to start with half the recommended dose due to the prolonged action.

In patients with hepatic dy

INTENDIS

Ultrabase Cream

Read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However, you still need to use Ultrabase carefully to get the best results from it.

  • Keep this leaflet. You may need to read it again.
  • Ask your pharmacist if you need more information or advice.
  • You must contact a doctor if your symptoms worsen or do not improve.
  • If you experience any side effect and this becomes serious, tell your doctor or pharmacist.

In this leaflet:

  • 1. What Ultrabase is and what it is used for
  • 2. Before you use Ultrabase
  • 3. How to use Ultrabase
  • 4. Possible side effects
  • 5. How to store Ultrabase
  • 6. Further information

What Ultrabase is and what it is used for

Ultrabase is a moisturiser that can be used to dilute skin preparations and is also used as a base for other medicines. It may be used as an alternative to topical corticosteroids (medicines put on the skin to reduce the redness and itchiness of certain skin problems) when they are being stopped. It may also be used alone after the topical corticosteroid is no longer used.

Before you use Ultrabase

Do not use Ultrabase

Uniphyllin Continus 200 mg, 300 mg and 400 mg prolonged-release tablets

Theophylline

Read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However you still need to take Uniphyllin Continus tablets carefully to get the best results from them.

  • Keep this leaflet. You may need to read it again.
  • Ask your pharmacist if you need more information or advice.
  • You must contact a doctor if your symptoms worsen or do not improve.
  • If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What Uniphyllin Continus tablets are and what they are used for
  • 2. Before you take Uniphyllin Continus tablets
  • 3. How to take Uniphyllin Continus tablets
  • 4. Possible side effects
  • 5. How to store Uniphyllin Continus tablets
  • 6. Further information

What Uniphyllin Continus tablets are and what they are used for

These tablets are used to treat asthma, long-term breathing difficulties such as chronic obstructive pulmonary disease and chronic bronchitis, and are sometimes used to treat heart failure.

They contain the active ingredient theophylline which belongs to a group of medicines called bronchodilators. Bronchodilat

1. Name Of The Medicinal Product

Uniroid-HC™ Suppositories

2. Qualitative And Quantitative Composition

Each suppository contains:

Hydrocortisone Ph.Eur 5.0 mg

Cinchocaine Hydrochloride BP 5.0 mg

3. Pharmaceutical Form

An off-white, odourless, smooth, suppository.

4. Clinical Particulars

4.1 Therapeutic Indications

Uniroid-HC Suppositories are indicated for use in the treatment of internal haemorrhoids for the short term relief of pain, irritation and associated pruritus ani.

4.2 Posology And Method Of Administration

Adults

Treatment with Uniroid-HC Suppositories should be limited to seven days. Patients should be advised to return to their doctor if the condition persists beyond this time.

Directions for use and dosage schedule:

Remove the plastic protective shell and insert a suppository as far as possible into the anus.

One suppository to be inserted twice a day (morning and evening) and after each bowel movement, or as prescribed by the doctor.

The suppositories may be used separately or concurrently with the ointment.

The Elderly

Dosage modifications are not required in the elderly.

Children

Uniroid-HC Suppositories are not recommended for use in children under 12 years of age unless directed by a doctor.

4.3 Contraindications

Known hypersensitivity to any of the constituents and to local anaesthetics. This product is contra-indicated in tuberculosis, anal thrush and most viral lesions of the skin including herpes simplex, vaccinia an

1. Name Of The Medicinal Product

UTINOR® 400 mg Tablets

2. Qualitative And Quantitative Composition

'Utinor' contains 400 mg of the active ingredient, norfloxacin.

For excipients, see 6.1

3. Pharmaceutical Form

'Utinor' is supplied as off-white oval tablets marked 'MSD 705'.

4. Clinical Particulars

4.1 Therapeutic Indications

Norfloxacin is a broad-spectrum, quinolone bactericidal agent indicated for the treatment of:

Upper and lower, complicated and uncomplicated, acute and chronic urinary tract infections. These infections include cystitis, pyelitis, chronic prostatitis and those urinary infections associated with urological surgery, neurogenic bladder or nephrolithiasis caused by bacteria susceptible to 'Utinor'.

Consideration should be given to official local guidance (e.g. national recommendations) on the appropriate use of bacterial agents.

Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available.

4.2 Posology And Method Of Administration

'Utinor' should be taken with a glass of water at least one hour before or two hours after a meal or milk ingestion. Multivitamins, products containing iron or zinc, antacids containing magnesium and aluminium, sucralfate or products containing didanosine should not be taken within 2 hours of administration of norfloxacin.

Susceptibility of the causative organism to 'Utinor' should be tested. However, therapy may be initiated before obtaining the results of these tests.

Diagnosis

1. Name Of The Medicinal Product

UNIPHYLLIN® CONTINUS® 200, 300 and 400 mg prolonged release tablets

2. Qualitative And Quantitative Composition

Tablets containing 200, 300 or 400 mg of Theophylline.

For excipients, see 6.1

3. Pharmaceutical Form

Prolonged release tablets

200 mg

Capsule shaped, white tablet, plain one side and 'U200' on the other.

   

300 mg

Capsule shaped, white tablet, plain one side and 'U300' on the other.

   

400 mg

Capsule shaped, white tablet with 'UNIPHYLLIN' on one side and the 'Napp logo' and 'U400' on the reverse.

4. Clinical Particulars

4.1 Therapeutic Indications

For the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis. Also indicated for the treatment of left ventricular and congestive cardiac failure.

4.2 Posology And Method Of Administration

1. Name Of The Medicinal Product

Ultravist® 370

2. Qualitative And Quantitative Composition

1ml contains 769mg of iopromide (equivalent to 370mg iodine).

3. Pharmaceutical Form

Aqueous solution for injection.

4. Clinical Particulars

4.1 Therapeutic Indications

X-ray contrast medium for computerised tomography, digital subtraction angiography, intravenous urography, venography (phlebography), arteriography, arthrography, hysterosalpingography and fistulography.

4.2 Posology And Method Of Administration

• General information

Experience shows that contrast medium is tolerated better if it is warmed to body temperature.

Intravenous urography

Adults: The minimum dose is 0.8ml/kg body weight Ultravist 370, (1ml/kg Ultravist 300 or 1.3ml/kg Ultravist 240). These doses should provide adequate filling of the ureters. It may be necessary to increase the dose in individual cases.

Children: The poor concentrating ability of the immature nephron of infantile kidneys necessitates the use of relatively high doses of contrast medium, i.e. for Ultravist 300:

Neonates: 4.0 ml/kg body weight
Babies: 3.0 ml/kg body weight
Small children: 1.5 ml/kg body weight

Computerised tomography

Cranial CT: The following dosages are recommended for cranial CT:

1. Name Of The Medicinal Product

Ultrabase®

2. Qualitative And Quantitative Composition

There are no active constituents.

3. Pharmaceutical Form

Cream

4. Clinical Particulars

4.1 Therapeutic Indications

For general use as:

- an emollient

- a diluent for dermatological preparations and

- a vehicle for various dermatological medicaments.

Additionally, it may be alternated with topical corticosteroids when the latter are being gradually withdrawn, and may be continued alone after complete withdrawal of the topical corticosteroid.

4.2 Posology And Method Of Administration

For topical administration as required.

4.3 Contraindications

Hypersensitivity to any of the components of Ultrabase.

4.4 Special Warnings And Precautions For Use

None stated.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None known.

4.6 Pregnancy And Lactation

None stated.

4.7 Effects On Ability To Drive And Use Machines

None known.

4.8 Undesirable Effects

None known.

4.9 Overdose

Not applicable. Ultrabase contains no active ingredients.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Ultrabase has no specific active ingredient, but the cream formulation has good emollient properties.

5.2 Pharmacokinetic Properties

None stated.

5.3 Preclinical Safety Data

There are no preclinical safety data which cou

1. Name Of The Medicinal Product

Unguentum M

2. Qualitative And Quantitative Composition

There is no specific active ingredient.

3. Pharmaceutical Form

Cream

4. Clinical Particulars

4.1 Therapeutic Indications

Unguentum M has emollient properties and is recommended for the symptomatic treatment of dermatitis, nappy rash, ichthyosis, eczema, protection of raw and abraded skin areas, pruritus and related skin conditions where dry scaly skin is a problem, and as a pre-bathing emollient for dry/eczematous skin, to alleviate drying effects.

Unguentum M is to be used as a diluent for various topical corticosteriod formulations in those instances where a lower strength preparation is considered desirable by the physician and as a general base for extemporaneous dispensing.

4.2 Posology And Method Of Administration

A thin application of the cream should be gently massaged into the skin three times daily or at appropriate intervals.

When used as a protective cream Unguentum M should be applied sparingly to the affected areas of the skin before, or immediately after, exposure to a potentially harmful factor.

4.3 Contraindications

Unguentum M should not be used:

- if hypersensitivity to any of the ingredients is known.

- near the eyes and on mucous membranes.

4.4 Special Warnings And Precautions For Use

Sorbic acid and Cetostearyl alcohol may cause local skin reactions, (e.g. contact dermatitis)

Propylenglycol may cause skin reactions.

Ingestion of Unguentum M should be avoided.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

1. Name Of The Medicinal Product

Ultravist® 240

2. Qualitative And Quantitative Composition

1ml contains 499mg of iopromide (equivalent to 240mg iodine).

3. Pharmaceutical Form

Aqueous solution for injection.

4. Clinical Particulars

4.1 Therapeutic Indications

X-ray contrast medium for computerised tomography, digital subtraction angiography, intravenous urography, venography (phlebography), arteriography, arthrography, hysterosalpingography and fistulography.

4.2 Posology And Method Of Administration

• General information

Experience shows that contrast medium is tolerated better if it is warmed to body temperature.

Intravenous urography

Adults: The minimum dose is 0.8ml/kg body weight Ultravist 370, (1ml/kg Ultravist 300 or 1.3ml/kg Ultravist 240). These doses should provide adequate filling of the ureters. It may be necessary to increase the dose in individual cases.

Children: The poor concentrating ability of the immature nephron of infantile kidneys necessitates the use of relatively high doses of contrast medium, i.e. for Ultravist 300:

Neonates: 4.0 ml/kg body weight
Babies: 3.0 ml/kg body weight
Small children: 1.5 ml/kg body weight

Computerised tomography

Cranial CT: The following dosages are

UTINOR 400 mg Tablets

(norfloxacin)

Read all of this leaflet carefully before you start taking this medicine.

  • Keep this leaflet. You may want to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What Utinor is and what it is used for
  • 2. Before you take Utinor
  • 3. How to take Utinor
  • 4. Possible side effects
  • 5. How to store Utinor
  • 6. Further information

What Utinor is and what it is used for

What Utinor is

Utinor contains a medicine called norfloxacin. This is an antibiotic which works against a large number of bacteria.

What Utinor is used for

Utinor is used for infections of the urinary system. It works by killing bacteria that can cause infections of your urinary system.

Before you take Utinor

Do not use Utinor if:

  • you are allergic (hypersensitive) to norfloxacin or any of the other ingredients of Utinor (listed in Section 6)
  • you are pregnant or thi

1. Name Of The Medicinal Product

Ultravist® 300

2. Qualitative And Quantitative Composition

1ml contains 623mg of iopromide (equivalent to 300mg iodine).

3. Pharmaceutical Form

Aqueous solution for injection.

4. Clinical Particulars

4.1 Therapeutic Indications

X-ray contrast medium for computerised tomography, digital subtraction angiography, intravenous urography, venography (phlebography), arteriography, arthrography, hysterosalpingography and fistulography.

4.2 Posology And Method Of Administration

• General information

Experience shows that contrast medium is tolerated better if it is warmed to body temperature.

Intravenous urography

Adults: The minimum dose is 0.8ml/kg body weight Ultravist 370, (1ml/kg Ultravist 300 or 1.3ml/kg Ultravist 240). These doses should provide adequate filling of the ureters. It may be necessary to increase the dose in individual cases.

Children: The poor concentrating ability of the immature nephron of infantile kidneys necessitates the use of relatively high doses of contrast medium, i.e. for Ultravist 300:

Neonates: 4.0 ml/kg body weight
Babies: 3.0 ml/kg body weight
Small children: 1.5 ml/kg body weight

Computerised tomography

Cranial CT: The following dosages are

1. Name Of The Medicinal Product

Urokinase medac 250,000 I.U.

Powder for solution for injection or infusion

2. Qualitative And Quantitative Composition

Each vial contains 250,000 I.U. of human urokinase extracted from human urine.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder for solution for injection or infusion

4. Clinical Particulars

4.1 Therapeutic Indications

Intravascular lysis of blood clots in the following conditions:

• extensive acute proximal deep vein thrombosis

• acute massive pulmonary embolism

• acute occlusive peripheral arterial disease with limb threatening ischemia

• thrombosed arteriovenous haemodialysis shunts

• thrombosed central venous catheters

4.2 Posology And Method Of Administration

Urokinase medac should only be used by physicians experienced in the management of thrombotic diseases in hospitals where adequate diagnostic and monitoring techniques are available.

Depending on the indication, the route of administration of Urokinase medac is by systemic intravenous infusion, by local intra-arterial catheter-directed infusion during arteriography, or by local instillation.

It must not be given by subcutaneous or intramuscular injection.

For instructions regarding reconstitution and further dilution, see section 6.6.

Adults

The dosage may be adjusted individually depending on the clinical condition. The following dose regimens should be used as a guideline.

Deep vein thrombosis

UNIVER 120 mg, 180 mg 240 mg Prolonged Release Hard Capsules

(Verapamil hydrochloride)

Read all of this leaflet carefully before you start taking this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What UNIVER is and what it is used for.
  • 2. Before you use UNIVER.
  • 3. How to use UNIVER.
  • 4. Possible side effects.
  • 5. How to store UNIVER.
  • 6. Further information.

What Univer Is And What It Is Used For

The name of this medicine is UNIVER prolonged release hard capsules and it comes in three strengths (120 mg, 180 mg and 240 mg).

The active ingredient in them is verapamil hydrochloride which belongs to a group of medicines called calcium channel blockers.

UNIVER is used to treat high blood pressure (hypertension) and chest pains caused by lack of oxygen getting to the heart (angina pectoris).

Before You Take Univer

Do not take UNIVER if you:

  • Are allergic (hypersensitive) to verapamil hydrochloride or any of the other ingredients of UNIVER.

1. Name Of The Medicinal Product

Urokinase medac 10,000 I.U.

Powder for solution for injection or infusion

2. Qualitative And Quantitative Composition

Each vial contains 10,000 I.U. of human urokinase extracted from human urine.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder for solution for injection or infusion

4. Clinical Particulars

4.1 Therapeutic Indications

Intravascular lysis of blood clots in the following conditions:

• extensive acute proximal deep vein thrombosis

• acute massive pulmonary embolism

• acute occlusive peripheral arterial disease with limb threatening ischemia

• thrombosed arteriovenous haemodialysis shunts

• thrombosed central venous catheters

4.2 Posology And Method Of Administration

Urokinase medac should only be used by physicians experienced in the management of thrombotic diseases in hospitals where adequate diagnostic and monitoring techniques are available.

Depending on the indication, the route of administration of Urokinase medac is by systemic intravenous infusion, by local intra-arterial catheter-directed infusion during arteriography, or by local instillation.

It must not be given by subcutaneous or intramuscular injection.

For instructions regarding reconstitution and further dilution, see section 6.6.

Adults

The dosage may be adjusted individually depending on the clinical condition. The following dose regimens should be used as a guideline.

Deep vein thrombosis

Uro

1. Name Of The Medicinal Product

UbretidTM.

2. Qualitative And Quantitative Composition

Active ingredient Distigmine bromide 5mg.

3. Pharmaceutical Form

Tablets.

4. Clinical Particulars

4.1 Therapeutic Indications

Anticholinesterase. Post-operative urinary retention. Post operative ileus and intestinal atony. To assist emptying of the neurogenic bladder. As an adjunct in the treatment of myasthenia gravis.

4.2 Posology And Method Of Administration

Adults

In prevention of urinary retention, ileus or intestinal atony following surgery:

One Ubretid tablet daily, half an hour before breakfast.

In neurogenic bladder:

One Ubretid tablet daily or on alternate days, half an hour before breakfast, on an empty stomach.

In myasthenia gravis:

Dosage to be individualised for each patient, dependent upon the severity of the condition, the degree and duration of response and the side effects encountered. The tablets should always be taken on an empty stomach half an hour before breakfast. Dosage should commence at 1 tablet daily and may be adjusted at intervals of three to four days to a total not exceeding 4 tablets daily.

Children

Up to 2 tablets daily according to age.

Elderly

No dosage adjustment is necessary for elderly patients.

Ubretid tablets are for oral administration.

4.3 Contraindications

Ubretid is contraind